* PXN VEGFA/B/C VEGFR2 SHC2 SRC CDC42 PLCG 1/2 SH2D2A PI3K MAPK14

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

AB 11 22 33 44 55 66 77 88 99 10  20  19  18  17  16  15  14  13  12  11  21  22  23  24  25  26  27  28.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Signal Transduction II Transduction Proteins & Second Messengers.

Supplemental Figures. Supplemental Figure 1. Top two canonical pathways clustering the potential predictive biomarkers. The Ingenuity IPA tool was used.

Properties of Addition and Multiplication. Commutative Property In the sum you can add the numbers in any order. a+b = b+a In the product you can multiply.

1 Hepatocellular Carcinoma Overview of Hepatocellular Carcinoma Epidemiology.

Compensatory Angiogenesis and Tumor Refractoriness Prof. Rajesh N Gacche Tumor Biology Laboratory, School of Life Sciences SRTM Univeristy, Nanded, India.

Supplemental Table 1. Oligonucleotide sequences used for mRNA expression analysis by qPCR. Primer name Forward Primer 5’- 3’Reverse Primer 5’-3’ KLK3 5’-GTGCTTGTGGCCTCTCG-3’

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

PDGF PDGFR Mitogenesis Actin Reorganization Figure 1. PI3K Raf-1 MEK c-fosc-jun MAP Kinase Erk Rac Rho Ras Grb2 mSos.

Growth factor PI3K PDK1/2 PIP 3 AKT CASP9 FOXO1 BAD CDKN1A CDKN1B MDM2 GSK3B CHUK mTOR PTEN miR-26ab/1297; miR-148/152; miR-103/107; miR-19; miR-425/489;

May 2013 Objective: to be able to multiply and divide expressions Skills: Absorption and Making Links By the end of the lesson: All: will be able to multiply.

Angiogenesis in rheumatologic disorders. New blood vessels De novo formation Formation from pre existing vessels Endothelial formation from mesenchymal.

Author(reference) down up Supplemental data S1. differentially expressed miRNAs in selected microarray studies Murakami (14)miR-18, miR-224miR-199a, miR-195,

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers Thomas X. Lu,

ANIMAL TARGET PREDICTION - TIPS

Oncogene activation Transcription DNA damage MDM2 CDKN2A MDM4 p53 ATR

Med Princ Pract 2016;25(suppl 2): DOI: /

Algebra substitution.

Figure 1 miRNA expression in multiple sclerosis lesions

Circuits & Boolean Expressions

Supplemental Figure and Tables Legends

تصنيف التفاعلات الكيميائية

Miriam Marqués, Francisco X. Real European Urology

Wild-Type RAS: Keeping Mutant RAS in CHK

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers Thomas X. Lu,

GRB2 SOS1/2 SHC 1/2/3/4 PDGFR PDGF EGFR EGF PKC SPHK 1/2 RAS RAF1

Florie Borel, Pavlina Konstantinova, Peter L.M. Jansen

John S. Tsang, Margaret S. Ebert, Alexander van Oudenaarden

C2 Can Do It, Too Cell Volume 121, Issue 2, Pages (April 2005)

Mechanisms of mast cell signaling in anaphylaxis

Supplementary Figure S1

Figure 3 Integrative signalling networks enable interactions

Regulating Cancer Stem Cells the miR Way

A microRNA profile comparison between thoracic aortic dissection and normal thoracic aorta indicates the potential role of microRNAs in contributing to.

Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets Benjamin P. Lewis, Christopher B. Burge,

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Математици-юбиляри.

MicroRNAs in Tfh Cells: Micromanaging Inflammaging

Peter Celec, Yoshikazu Yonemitsu Pathophysiology

Vascular Endothelial Growth Factor (VEGF) Pathway

Perimeter and Area of Similar Figures

Edwards Allen, Zhixin Xie, Adam M. Gustafson, James C. Carrington Cell

How to present a scientific paper

Andrew D. Bosson, Jesse R. Zamudio, Phillip A. Sharp Molecular Cell

Basic elements of triangle

John S. Tsang, Margaret S. Ebert, Alexander van Oudenaarden

Signaling Interplay in Ras Superfamily Function

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

Volume 24, Issue 5, Pages (March 2013)

Figure Overview.

Gene expression profiling of human bone marrow-derived mesenchymal stem cells during adipogenesis DOI: /FHC.a Gene-act-network according.

Pathway analysis of genes upregulated after RSV infection.

Figure Overview.

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Hilde van Hattum, Herbert Waldmann Chemistry & Biology

Volume 24, Issue 5, Pages (March 2013)

Cell Signalling: Receptor orphans find a family

Platelet-derived growth factor (PDGF) signalling pathway.

Volume 24, Issue 10, Pages (October 2016)

Circuits & Boolean Expressions

Fig. 1. Expression of the five miRNAs encoded by two miRNA clusters in mouse sperm and oocytes.(A) qPCR analyses of levels of miR-16 (positive control),

Fig. 1. Expression of the five miRNAs encoded by two miRNA clusters in mouse sperm and oocytes.(A) qPCR analyses of levels of miR-16 (positive control),

c-Raf in KRas Mutant Cancers: A Moving Target

Properties of Numbers Review Problems.

The critical roles of miR-23a and miR-27a in colorectal cancer progression. miR-23a primarily increases cell motility through downregulation of its target.

Summary of the experimental strategy and key findings of Mitra and colleagues (10). Summary of the experimental strategy and key findings of Mitra and.

Figure 5-1 Molecular Biology of the Cell (© Garland Science 2008)

Presentation transcript:

* PXN VEGFA/B/C VEGFR2 SHC2 SRC CDC42 PLCG 1/2 SH2D2A PI3K MAPK14 miR-203; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-141/200a; miR-137; miR-1/206; miR-31; miR-144; miR-153; miR-214/761;miR-184; miR-208/208ab; miR-22; miR-499/499-5p; miR-182; miR-10; miR-503; miR-9; miR-138; miR-24; miR-204/211; miR-218 PXN miR-200bc/429; miR-204/211; miR-135; miR-218; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-182; miR-101; miR-96/1271; miR-1/206; miR-125/351; miR-205; miR-30a/30a-5p/30b/30b-5p/30cde/384-5p; miR-214/761; miR-129/129-5p; miR-155; miR-103/107; miR-455/455-5p; miR-223; miR-181 VEGFA/B/C VEGFR2 SHC2 SRC CDC42 PLCG 1/2 SH2D2A PI3K MAPK14 MAPKAPK2 HSPB2 FAK CALN1 NFAT5 PKC SPK RAS RAF1 MAP2K MAPK1 KAT5 IP3 Ca2+ DAG miR-200bc/429; miR-221/222; miR-455/455-5p; miR-138; miR-15/16/195/424/497; miR-338/338-3p; miR-23ab; miR-129/129-5p; miR-141/200a; miR-375; miR-214/761 VEGFA: miR-29abc; miR-15/16/195/424/497; miR-205;miR-200bc/429; miR-383; miR-140/140-5p/876-3p; miR-203; miR-199/199-5p; miR-503; miR-1/206; miR-17-5p/20/93.mr/106/519.d; miR-103/107; miR-106/302; miR-150; miR-24; miR-139-5p; miR-34a/34b-5p/34c/34c-5p/449/449abc/699 VEGFB: miR-140/140-5p/876-3p; miR-101; miR-27ab; miR-125/351; miR-128; miR-375 VEGFC: miR-128; miR-27ab; miR-133; miR-101 miR-29abc; miR-1/206; miR-18ab; miR-137; miR-25/32/92/92ab/363/367; miR-129/129-5p; miR-27ab; miR-141/200a; miR-200bc/429; miR-31; miR-128 miR-9; miR-338/338-3p; miR-218; miR-146 FAK: miR-135; miR-138; miR-106/302; miR-196ab; miR-7/7ab; miR-221/222; miR-551ab; miR-145; miR-17-5p/20/93.mr/106/519.d; miR-199/199-5p; miR-139-5p; miR-25/32/92/92ab/363/367; miR-23ab Paxillin: miR-203; miR-145; miR-216/216b; miR-137; miR-199/199-5p; miR-132/212; miR-24; miR-27ab; miR-125/351; miR-140/140-5p/876-3p; miR-9; miR-218; miR-122; miR-128 miR-103/107; miR-24; miR-15/16/195/424/497 * SPHK1: miR-124/506; miR-1/206 SPHK2: miR-153; miR-130/301; miR-338/338-3p; miR-1/206; miR-19; miR-25/32/92/92ab/363/367; miR-184; miR-137; miR-181; miR-451; miR-503; miR-383; miR-15/16/195/424/497; miR-31 KRAS: miR-181; miR-27ab; miR-143; miR-217; miR-96/1271; miR-132/212; miR-155; miR-193ab; miR-19; miR-365; miR-199/199-5p; miR-30a/30a-5p/30b/30b-5p/30cde/384-5p; miR-141/200a; miR-216/216b; miR-1/206; miR-425/489; miR-129/129-5p; miR-214/761; miR-146; miR-383; miR-190; miR-204/211; miR-23ab; miR-15/16/195/424/497; miR-200bc/429; miR-216/216a; miR-125/351; miR-128; miR-101; miR-218; miR-31; miR-144; miR-7/7ab; miR-194; miR-142-3p; miR-490/490-3p HRAS: miR-338/338-3p miR-203; miR-106/302; miR-10; miR-148/152; miR-155; miR-19; miR-124/506; miR-132/212; miR-124/506; miR-122; miR-203; miR-143; miR-142-3p; miR-25/32/92/92ab/363/367; miR-33/33ab; miR-129/129-5p; miR-24 miR-7/7ab; miR-19; miR-15/16/195/424/497; miR-125/351; miR-135; miR-455/455-5p; miR-503; miR-139-5p; miR-150; miR-1/206; miR-143 MAP2K1: miR-181; miR-15/16/195/424/497; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-148/152; miR-144; miR-96/1271; miR-130/301; miR-203; miR-503; miR-139-5p; miR-23ab MAP2K2: miR-503 miR-204/211; miR-128; miR-132/212; miR-23ab; miR-150; miR-30a/30a-5p/30b/30b-5p/30cde/384-5p; miR-27ab; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-190; miR-214/761; miR-10; miR-187; miR-29abc; miR-216/216a; miR-15/16/195/424/497; miR-122; miR-9; miR-125/351 miR-129/129-5p; miR-137; miR-96/1271; miR-22; miR-34a/34b-5p/34c/34c-5p/449/449abc/699 CALN1: miR-143; miR-218; miR-25/32/92/92ab/363/367; miR-33/33ab; miR-138; miR-200bc/429; miR-153; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-130/301; miR-129/129-5p; miR-183; miR-191; miR-122; miR-214/761; miR-199/199-5p; miR-22; miR-137; miR-133; miR-128; miR-135; let-7/98; miR-144; miR-21/590-5p; miR-205; miR-155; miR-7/7ab; miR-187; miR-145; miR-19; miR-204/211; miR-106/302; miR-103/107; miR-223; miR-1/206; miR-150; miR-375; miR-193ab; miR-23ab; miR-217; miR-203; miR-125/351; miR-383; miR-182; miR-192/215; miR-216/216b; miR-499/499-5p; miR-208/208ab; miR-132/212; miR-17-5p/20/93.mr/106/519.d; miR-30a/30a-5p/30b/30b-5p/30cde/384-5p; miR-15/16/195/424/497; miR-139-5p; miR-503; miR-338/338-3p; miR-216/216a; miR-9; miR-26ab/1297; miR-221/222 NFAT5: miR-30a/30a-5p/30b/30b-5p/30cde/384-5p; miR-17-5p/20/93.mr/106/519.d; miR-205; miR-181; miR-148/152; miR-217; miR-194; miR-1/206; miR-124/506; miR-21/590-5p; miR-33/33ab; miR-150; miR-146; miR-132/212; miR-29abc; miR-190; miR-15/16/195/424/497; miR-7/7ab; miR-216/216b; miR-25/32/92/92ab/363/367; miR-203; miR-365; miR-183; miR-103/107; miR-31; miR-143; miR-122; miR-27ab; miR-18ab; miR-140/140-5p/876-3p; miR-10; miR-24; miR-22; miR-128; miR-210; miR-221/222; miR-135; miR-155; miR-101; miR-133; miR-383; miR-139-5p; miR-153; miR-200bc/429; miR-216/216a; miR-129/129-5p; miR-138; miR-499/499-5p; miR-9; miR-204/211; miR-196ab; miR-192/215; miR-490/490-3p; miR-375; miR-338/338-3p; miR-141/200a miR-33/33ab; miR-19; miR-124/506; miR-128; miR-23ab; miR-22; miR-125/351; miR-24; miR-27ab; miR-216/216b; miR-375; miR-143; miR-133; miR-146; miR-145; miR-141/200a; miR-214/761; miR-130/301; miR-10 miR-137; miR-31; miR-9; miR-24; miR-7/7ab; miR-425/489; miR-19; miR-183; miR-150; miR-22; miR-125/351; miR-96/1271; miR-182; miR-214/761 miR-214/761

* PRKCA: miR-205; miR-203; miR-199/199-5p; miR-23ab; miR-223; miR-219/219-5p; miR-139-5p; miR-17-5p/20/93.mr/106/519.d; miR-132/212; miR-150; miR-200bc/429;miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-129/129-5p; miR-216/216b; miR-375; miR-15/16/195/424/497; miR-216/216a; miR-22; miR-338/338-3p; miR-141/200a; miR-9; miR-24; miR-183; miR-1/206; miR-193ab; miR-210; miR-125/351; miR-214/761; miR-10; miR-503; miR-181; miR-122; miR-146; miR-138; miR-194; miR-204/211; miR-490/490-3p; miR-192/215; miR-217; miR-7/7ab PRKCB1: miR-183; miR-129/129-5p; miR-203; miR-141/200a; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-194; miR-182; miR-26ab/1297; miR-106/302; let-7/98; miR-365; miR-184; miR-148/152; miR-33/33ab; miR-29abc; miR-7/7ab PRKCD: miR-26ab/1297; miR-181; miR-129/129-5p; miR-490/490-3p; miR-218; miR-27ab; miR-15/16/195/424/497 PRKCG: miR-338/338-3p; miR-503; miR-140/140-5p/876-3p; miR-135; miR-1/206 PRKCE: miR-31; miR-96/1271; miR-129/129-5p; miR-216/216a; miR-101; miR-141/200a; miR-146; miR-205; miR-103/107; miR-1/206; miR-33/33ab; miR-182; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-143; miR-223; miR-10; miR-181; miR-383; miR-144; miR-23ab; miR-22; miR-21/590-5p; miR-132/212; miR-218; miR-216/216b; miR-25/32/92/92ab/363/367; miR-139-5p; miR-106/302; miR-125/351; miR-29abc; miR-19 PRKCH: miR-24; miR-205; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-216/216a; miR-204/211; miR-27ab; miR-17-5p/20/93.mr/106/519.d; miR-145; miR-383; miR-216/216b; miR-221/222; miR-200bc/429; miR-455/455-5p; miR-214/761 PRKCI: miR-203; miR-455/455-5p; miR-103/107; miR-219/219-5p; miR-146; miR-365; miR-10; miR-155; miR-183; miR-199/199-5p; miR-23ab; miR-141/200a;miR-204/211;miR-15/16/195/424/497;miR-129/129-5p;miR-24;miR-33/33ab;miR-200bc/429;miR-96/1271;miR-29abc;miR-1/206;miR-150;miR-490/490-3p;miR-217;miR-138;miR-18ab;miR-216/216a;miR-182;miR-181 PRKCQ: miR-26ab/1297; miR-34a/34b-5p/34c/34c-5p/449/449abc/699; miR-192/215; miR-25/32/92/92ab/363/367; miR-203; miR-183; miR-193ab; miR-221/222; miR-137; miR-31; miR-214/761; miR-383; miR-200bc/429 PRKCZ: miR-148/152; miR-15/16/195/424/497; miR-338/338-3p; miR-503 Supplemental Figure 3. Overview of VEGF signaling. Summary of VEGF signaling and predicted miRNA interactions. miRNAs that were described to be downregulated in renal cell carcinoma are highlighted in green, while upregulated miRNAs are highlighted in red; all other potential interactions are highlighted in black. Target interactions were predicted with TargetScan 5.1. miRNAs presented in this figure are all highly conserved among vertebrates; for a list of other miRNAs see Supplement Table 4.